Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Extends License for Genome Therapeutics Database

NEW YORK, Dec 6 - Genome Therapeutics said Wednesday that Bristol-Myers Squibb had renewed its license for the PathoGenome database, extending a subscription that began in 1997.

Under the terms of the agreement, Bristol-Myers Squibb will continue to have non-exclusive access to the database and will pay annual subscription fees as well as milestone payments and royalties on any small molecules developed as a result of the collaboration. Genome Therapeutics retains rights associated with the therapeutic and vaccine use of bacterial genes or gene products derived from the database.  

No other terms were disclosed.

" Through mining the PathoGenome Database, we have been able to dramatically expand the number of potential drug targets in our anti-infectives pipeline," John Barrett, executive director of infectious diseases research at Bristol-Myers Squibb, said in a statement.

Genome Therapeutics considers new anti-infectives to be leading candidates for the first commercial products based on genomic data.

The PathoGenome database offers functionally annotated sequence information on over 30 microbial pathogens, including Staphylococcus , Pseudomonas , Streptococcus , Enterococcus , Acinetobacter , Aspergillus , Bacteroides , Enterobacter , Klebsiella , and Candida species.

Originally available only by subscription, the database has been available since August on a pay-per-use basis through Compugen’s search engine The fee is based on the amount of information accessed per search.  

Other subscribers to the database include Aventis, Bayer, bioMerieux, and Schering-Plough.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.